Skip to main content

Market Overview

Recap: Biohaven Pharmaceutical Q4 Earnings



Shares of Biohaven Pharmaceutical (NYSE:BHVN) decreased 0.1% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 5.61% year over year to ($2.69), which beat the estimate of ($2.97).

Revenue of $35,114,000 up by 0.00% year over year, which beat the estimate of $28,230,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Biohaven Pharmaceutical hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Mar 01, 2021

Time: 08:30 AM

ET Webcast URL:


Company's 52-week high was at $100.77

52-week low: $26.56

Price action over last quarter: down 1.69%

Company Description

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.


Related Articles (BHVN)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at